Norbert G. Riedel has a wide range of experience in everything from oncology and therapeutic proteins, to biopharmaceutical and biotechnological development. Dr. Riedel’s resume boasts global cultural literacy, as he has studied, taught and worked in Europe as well as North America. Having previously led a company through the IPO process, Dr. Riedel has intimate knowledge of business development and a keen eye for growth opportunities, and extensive experience managing talent and human capital management matters.
Dr. Riedel has served as a member of our board of directors since May 2013 and was appointed chairperson of our Compensation Committee in August 2013 until April 2022 and was appointed chairperson of the Science and Medicine Committee in April 2022.
From 2001 to 2013, he served as Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017 and on the board of Cerevel Therapeutics Holdings, Inc. from October 2020 until it was acquired in August 2024. Dr. Riedel served as Executive Chairperson of Aptinyx Inc., a biopharmaceutical company, from January 2022 to May 2023, and also served as its Chief Executive Officer from September 2015 to December 2021 and President from September 2015 to December 2020. Dr. Riedel served as Chief Executive Officer and President of Naurex, Inc, from January 2014 to September 2015. Dr. Riedel currently serves on the boards of directors of Eton Pharmaceuticals, Inc., a development stage pharmaceutical company, where he also serves as Chairperson of the board, the Illinois Biotechnology Industry Organization and Angitia Biopharmaceuticals. Dr. Riedel is also a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University’s Feinberg School of Medicine. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.
What is Norbert G. Riedel's net worth?
The estimated net worth of Norbert G. Riedel is at least $1.34 million as of February 27th, 2026. Mr. Riedel owns 7,024 shares of Jazz Pharmaceuticals stock worth more than $1,337,791 as of March 3rd. This net worth estimate does not reflect any other assets that Mr. Riedel may own. Learn More about Norbert G. Riedel's net worth.
How do I contact Norbert G. Riedel?
Has Norbert G. Riedel been buying or selling shares of Jazz Pharmaceuticals?
During the last ninety days, Norbert G. Riedel has sold $655,680.00 of Jazz Pharmaceuticals stock. Most recently, Norbert G. Riedel sold 3,415 shares of the business's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $192.00, for a transaction totalling $655,680.00. Following the completion of the sale, the director now directly owns 7,024 shares of the company's stock, valued at $1,348,608. Learn More on Norbert G. Riedel's trading history.
Who are Jazz Pharmaceuticals' active insiders?
Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Heather McSharry (Director), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Norbert Riedel (Director), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?
During the last year, Jazz Pharmaceuticals insiders bought shares 2 times. They purchased a total of 101,621 shares worth more than $9,992,963.00. During the last year, insiders at the specialty pharmaceutical company sold shares 24 times. They sold a total of 223,142 shares worth more than $39,191,342.56. The most recent insider tranaction occured on February, 27th when CAO Patricia Carr sold 1,117 shares worth more than $213,246.47. Insiders at Jazz Pharmaceuticals own 4.3% of the company.
Learn More about insider trades at Jazz Pharmaceuticals. Information on this page was last updated on 2/27/2026.
